亚宝药业集团股份有限公司关于减少注册资本及修订《公司章程》的公告

Group 1 - The company has approved a share buyback plan to reduce its registered capital by repurchasing shares through centralized bidding, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [2][35] - As of November 14, 2025, the company repurchased a total of 8,000,000 shares, reducing the total number of shares from 700,000,046 to 692,000,046, and consequently decreasing the registered capital from RMB 700,000,046 to RMB 692,000,046 [3][7] - The company has revised its articles of association to reflect the reduction in registered capital, with no other changes to the remaining content [4][7] Group 2 - The company has agreed to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87,188,740, resulting in the company retaining only 5% of the subsidiary's shares [9][12] - The transaction is aimed at optimizing the company's asset structure and resource allocation, enhancing operational efficiency, and is expected to increase the company's profit by approximately RMB 59 million for the year 2025 [31] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require shareholder approval [13][17]